Contact Us
Menu
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Events
News
Posts
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Events
News
Posts

About Us

Biocytogen: Innovative Models to Empower Antibody Discovery

Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ Mouse), and in vivo/in vitro preclinical validation studies. With facilities in the US and China, our CRO division provides models and preclinical services to clients around the globe. In addition, we have a scientific team working on in-house research and discovery of novel antibody therapeutics for licensing and co-development partnerships. To learn more about our asset licensing division, clinical subsidiary, and executive leadership, visit the links below:

Our Sites
Our Leadership

Our Missions

  • Advance life sciences with high-quality and customized models to push the boundary of utilization of humanized target models in biomedical research
  • Develop technological platforms to accelerate next-generation drug discovery and development
  • Empower scientists in drug discovery by providing the necessary expertise to eliminate bottlenecks in research
  • Be a global leader in providing seamless preclinical services to our clients

    • Our Milestones
    Aug 2023
    Waltham, MA Facility Opening
    Biocytogen Announces Grand Opening of Waltham, MA Facility

    Biocytogen Pharmaceuticals announced the grand opening of a new 37,000 sqft. facility in Waltham, MA for its US-based subsidiary, Biocytogen Boston Corporation. The state-of-the-art facility, conveniently located at 300 Third Avenue, will triple Biocytogen Boston’s workspace, and includes a climate-controlled 4,000 cage vivarium, cell culture and procedure suites, and an open design concept to facilitate collaboration among employees and visiting clients.

    May 2023
    New Office Opening
    Biocytogen Opens San Francisco Office to Accelerate Globalization

    Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) has announced the opening of a new office in San Francisco, California, USA. The new space will aim to accelerate the globalization of Biocytogen’s businesses.

    Jan 2023
    Product Launch
    Biocytogen Launches RenNano® Mouse

    Biocytogen officially launches its fully human heavy chain antibody platform, RenNano, the third member of the RenMice family. Together, Biocytogen’s three RenMice platforms allow for the streamlined discovery and development of fully human monoclonal antibodies, bispecific/multispecific antibodies and single-domain antibodies (sdAbs, or nanobodies).

    Sept 2022
    HKEX Listing
    Biocytogen's Listing Ceremony

    Biocytogen announced the company’s official listing on the Main Board of the Stock Exchange of Hong Kong. Government representatives, shareholders, agencies, collaborative partners, and employee representatives attended the listing ceremony.

    March 2022
    Expansion
    Grand Opening in Germany!

    Announced the opening of the Biocytogen Europe Innovation Center (BEIC) in Heidelberg, Germany.

    June 2021
    Phase II
    YH001 & YH003 Phase II Clinical Trials

    Obtained approval from the FDA to commence Phase II clinical trials for YH001 and YH003 in the US.

    June 2021
    New Financing
    Tens of Millions in Financing
    Completed a new round of financing totaling tens of millions of dollars.
    Sept 2020
    RenMice
    RenMice HiTS Platform Financing

    Completion of D+ round financing, enabling progression of the RenMice HiTS Platform initiative.

    August 2020
    Merger
    Biocytogen & Eucure
    Biocytogen merges with Eucure Biopharma, aiming to create innovative antibody drugs to improve human health worldwide.
    May 2020
    Clinical Trials
    YH001 & YH002 Approved
    Anti-CTLA-4 and OX40 antibodies YH001 and YH002 approved for clinical trials in China
    March 2020
    Platform Launch
    RenMice HiTS Platform Launch
    RenMice HiTS Platform initiative launched, signifying Biocytogen's transformation to a biotechnology company
    January 2020
    Clinical Trials
    YH002 Clinical Trials Approved in U.S.
    Anti-OX40 antibody YH002 was approved for clinical trials in the United States
    October 2019
    Clinical Trials
    YH001 Clinical Trials Approved in U.S.
    Anti-CTLA-4 antibody YH001 was approved for clinical trials in the United States
    August 2019
    New Technology
    Rise of RenMab
    Developed RenMab Mouse, a fully human antibody mouse model; Closed D-round funding in July
    April 2018
    Scaling Up
    Venture Funding
    Received C-round funding from SDIC Venture Capital, 3E Bioventures, Cowin Capital Group and Oriza Holdings
    February 2018
    New Sites
    Boston & Shanghai Sites
    Boston and Shanghai sites opened for business
    2016
    Company Matures
    Haimen Animal Center Opens
    Haimen Animal Center began operations; AAALAC accreditation earned; Antibody Discovery Service Platform established; B-NDG™ and a comprehensive variety of humanized immune checkpoint mice were supplied to clients
    2016
    Company Expansion
    Preclinical Services & New Funding
    Established preclinical services platform; Raised B-round funding from SDIC Venture Capital and BioVeda China Fund
    2014
    Mouse Models
    New Mouse Models Developed
    Developed B-NDG™ mice (highly immune deficient) and B-hPD-1, the first humanized immune-checkpoint mouse model
    2011
    Gene Editing
    ESC/HR Gene Editing Platform
    Developed ESC/HR-based gene editing technology platform and delivered gene editing services to our first customer.
    2009
    Origins
    Biocytogen Established

    Beijng Biocytogen Co., Ltd (Headquarters) established

    Back to top